Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort

News
Video

Related Videos
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Benjamin Garmezy, MD
Related Content
Bruna Pellini, MD, of Moffitt Cancer Center and Research Institute

Pellini Discusses Immunotherapies and Shortcomings of ctDNA in Perioperative NSCLC

May 16th 2024
Article
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

May 13th 2024
Podcast
Rebecca A. Dent, MD, MSc, of National Cancer Center Singapore and Duke-NUS Medical School

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024
Article
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

May 9th 2024
Podcast
FDA

FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024
Article
Timothy L. Cannon, MD

Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer

May 15th 2024
Article